Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 11:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 392 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Part 1 Clear all

Recruiting Phase 1Phase 2 Interventional

PS-002 for the Treatment of IgA Nephropathy in Adults

NCT07182227

View directory record Official record

Conditions: Immunoglobulin A (IgA) Nephropathy
Interventions: PS-002; Genetic
Lead sponsor: Purespring Therapeutics Limited; Industry
Eligibility: 18 Years and older

Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Miami, Florida • Baltimore, Maryland • Ann Arbor, Michigan

Source: ClinicalTrials.gov public record

Updated Mar 19, 2026 · Synced May 21, 2026, 11:45 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants

NCT04484337

View directory record Official record

Conditions: HIV Infections
Interventions: Cabotegravir sodium (Oral Lead In), Cabotegravir 400 mg/mL, Cabotegravir 200 mg/mL, Topical non-steroidal anti-inflammatory drug, Topical steroid, Placebo creams/gels, Recombinant human hyaluronidase PH20 (rHuPH20); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years

Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Orlando, Florida • Las Vegas, Nevada • Berlin, New Jersey + 1 more

Source: ClinicalTrials.gov public record

Updated Dec 3, 2023 · Synced May 21, 2026, 11:45 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease

NCT05644977

View directory record Official record

Conditions: Healthy Participants, Alzheimer's Disease Dementia
Interventions: Emraclidine, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 55 Years to 90 Years

Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 11
States / cities: Cypress, California • San Diego, California • Hialeah, Florida + 8 more

Source: ClinicalTrials.gov public record

Updated May 1, 2025 · Synced May 21, 2026, 11:45 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003

NCT01725594

View directory record Official record

Conditions: Dyslipidemia
Interventions: CAT 2003, Placebo; Drug
Lead sponsor: Catabasis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Cincinnati, Ohio

Source: ClinicalTrials.gov public record

Updated Jul 10, 2013 · Synced May 21, 2026, 11:45 PM EDT

Completed Phase 1 Interventional

A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)

NCT05797753

View directory record Official record

Conditions: Amyotrophic Lateral Sclerosis, Healthy Volunteer
Interventions: SAR443820, Erythromycin ethyl succinate, Itraconazole; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Source: ClinicalTrials.gov public record

Updated Jan 2, 2025 · Synced May 21, 2026, 11:45 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients

NCT01795339

View directory record Official record

Conditions: Healthy Elderly Volunteers, Mild-to-moderate Alzheimer's Disease Patients
Interventions: AZD3293, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 55 Years to 80 Years

Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Glendale, California

Source: ClinicalTrials.gov public record

Updated Apr 2, 2014 · Synced May 21, 2026, 11:45 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults

NCT05109390

View directory record Official record

Conditions: Healthy
Interventions: Danicopan, Cyclosporine, Tacrolimus, Calcium Carbonate, Aluminum/Magnesium Hydroxide/Simethicone, Omeprazole; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Source: ClinicalTrials.gov public record

Updated Nov 4, 2021 · Synced May 21, 2026, 11:45 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess PDM608 in Healthy Adult Subjects

NCT05950906

View directory record Official record

Conditions: Parkinson Disease
Interventions: PDM608, Placebo; Drug
Lead sponsor: Calibr, a division of Scripps Research; Other
Eligibility: 18 Years to 65 Years

Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Source: ClinicalTrials.gov public record

Updated Nov 17, 2025 · Synced May 21, 2026, 11:45 PM EDT

Active, not recruiting Phase 2 Interventional

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

NCT04482309

View directory record Official record

Conditions: Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
Interventions: Trastuzumab deruxtecan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years

Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 12
States / cities: Duarte, California • Santa Rosa, California • Chicago, Illinois + 8 more

Source: ClinicalTrials.gov public record

Updated Apr 8, 2026 · Synced May 21, 2026, 11:45 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A PK Comparability Study of Two Different Amlitelimab Drug Products in Healthy Participants

NCT05796479

View directory record Official record

Conditions: Healthy Volunteers
Interventions: Amlitelimab DP1, Amlitelimab DP2; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Hialeah, Florida

Source: ClinicalTrials.gov public record

Updated Sep 18, 2025 · Synced May 21, 2026, 11:45 PM EDT

Terminated Phase 1 Interventional Results available

Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)

NCT06179407

View directory record Official record

Conditions: Narcolepsy
Interventions: MK-6552, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 5
States / cities: Colorado Springs, Colorado • Brandon, Florida • Atlanta, Georgia + 2 more

Source: ClinicalTrials.gov public record

Updated Apr 13, 2026 · Synced May 21, 2026, 11:45 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single Ascending Doses of CC-92480 in Healthy Subjects

NCT03803644

View directory record Official record

Conditions: Healthy Volunteer
Interventions: CC-92480; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Daytona Beach, Florida

Source: ClinicalTrials.gov public record

Updated May 6, 2020 · Synced May 21, 2026, 11:45 PM EDT

Not listed Phase 1 Interventional

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

NCT02637531

View directory record Official record

Conditions: Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E), Squamous Cell Cancer of the Head and Neck (Part E), Triple Negative Breast Cancer (Part F), Adrenocortical Carcinoma (Part G), Mesothelioma (Part G), High-circulating Myeloid-derived Suppressor Cells (Part H)
Interventions: IPI-549 (eganelisib), Nivolumab; Drug
Lead sponsor: Infinity Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 11
States / cities: San Diego, California • Santa Monica, California • Port Saint Lucie, Florida + 6 more

Source: ClinicalTrials.gov public record

Updated Apr 3, 2022 · Synced May 21, 2026, 11:45 PM EDT

Completed Phase 1Phase 2 Interventional

Study of DF9001 in Patients With Advanced Solid Tumors

NCT05597839

View directory record Official record

Conditions: Solid Tumor, Adult
Interventions: DF9001, KEYTRUDA® (pembrolizumab); Drug
Lead sponsor: Dragonfly Therapeutics; Industry
Eligibility: 18 Years and older

Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 17
States / cities: Gilbert, Arizona • Phoenix, Arizona • Irvine, California + 14 more

Source: ClinicalTrials.gov public record

Updated Oct 28, 2025 · Synced May 21, 2026, 11:45 PM EDT

Completed No phase listed Observational

Research Participants Perceptions of Their Experience in Clinical Studies

NCT00729534

View directory record Official record

Conditions: Participant Satisfaction
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older

Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Source: ClinicalTrials.gov public record

Updated Oct 5, 2017 · Synced May 21, 2026, 11:45 PM EDT

Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)

NCT05277571

View directory record Official record

Conditions: Atopic Dermatitis
Interventions: UCB1381, Placebo; Biological · Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 273 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 16
States / cities: Beverly Hills, California • Glendale, California • Los Angeles, California + 13 more

Source: ClinicalTrials.gov public record

Updated Oct 19, 2025 · Synced May 21, 2026, 11:45 PM EDT

Recruiting Phase 1Phase 2 Interventional

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

NCT07262619

View directory record Official record

Conditions: Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer, Endometrial Cancer, Mismatch Repair Deficient or MSI-High Solid Tumors
Interventions: EIK1005, pembrolizumab (KEYTRUDA® ); Drug
Lead sponsor: Eikon Therapeutics; Industry
Eligibility: 18 Years and older

Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Morristown, New Jersey • New York, New York • Houston, Texas

Source: ClinicalTrials.gov public record

Updated Apr 7, 2026 · Synced May 21, 2026, 11:45 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

NCT04839393

View directory record Official record

Conditions: Healthy Volunteer
Interventions: PF-06882961 followed by PF-06882961/PF-06865571, PF-06882961/PF-06865571 followed by PF-06882961, PF-06882961 + PF-06865571; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Tustin, California

Source: ClinicalTrials.gov public record

Updated Aug 20, 2023 · Synced May 21, 2026, 11:45 PM EDT

Recruiting Phase 3 Interventional

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

NCT06597019

View directory record Official record

Conditions: Familial Hypercholesterolemia - Heterozygous
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 11 Years

Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 9
States / cities: San Francisco, California • Washington D.C., District of Columbia • Boca Raton, Florida + 4 more

Source: ClinicalTrials.gov public record

Updated May 14, 2026 · Synced May 21, 2026, 11:45 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants

NCT06054464

View directory record Official record

Conditions: Healthy Volunteers
Interventions: PC14586, Rabeprazole, Famotidine; Drug
Lead sponsor: PMV Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Source: ClinicalTrials.gov public record

Updated Nov 12, 2024 · Synced May 21, 2026, 11:45 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Part 1: Dose-Finding of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users

NCT07404306

View directory record Official record

Conditions: General Anesthesia
Interventions: HSK3486, propofol, Placebo; Drug
Lead sponsor: Haisco-USA Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Source: ClinicalTrials.gov public record

Updated Feb 22, 2026 · Synced May 21, 2026, 11:45 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants

NCT05899738

View directory record Official record

Conditions: Healthy Volunteers
Interventions: Iberdomide; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Daytona Beach, Florida

Source: ClinicalTrials.gov public record

Updated Jul 25, 2024 · Synced May 21, 2026, 11:45 PM EDT

Completed Phase 4 Interventional Results available

EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events

NCT01069003

View directory record Official record

Conditions: Coronary Artery Disease
Interventions: Placebo Arm, Thienopyridine Therapy, Surveillance Arm; Drug · Device
Lead sponsor: Medtronic Vascular; Industry
Eligibility: 19 Years and older

Enrollment: 2,272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Anderson, South Carolina

Source: ClinicalTrials.gov public record

Updated Jan 19, 2016 · Synced May 21, 2026, 11:45 PM EDT

Active, not recruiting Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)

NCT06847854

View directory record Official record

Conditions: Diabetic Macular Edema
Interventions: RO7497372; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 37
States / cities: Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 34 more

Source: ClinicalTrials.gov public record

Updated Apr 19, 2026 · Synced May 21, 2026, 11:45 PM EDT